Immuneering Corp
جودة البيانات: 83%
IMRX
NASDAQ
Manufacturing
Chemicals
KWD 5.52
▼
KWD 0.14
(-2.47%)
القيمة السوقية: 358.82 M
السعر
KWD 5.55
القيمة السوقية
358.82 M
نطاق اليوم
—
نطاق 52 أسبوعًا
—
حجم التداول
—
فتح —
متوسط 50 يوم / 200 يوم
—
متوسط 50 يوم / 200 يوم
—
Quick Summary
النقاط الرئيسية
Negative free cash flow of -45.49 M
النمو
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
الجودة
Return on Equity
-43.61%
أعلى من متوسط القطاع (-54.47%)
ROIC-35.52%
Net MarginN/A
Op. MarginN/A
الأمان
Debt / Equity
N/A
Current Ratio24.00
Interest CoverageN/A
التقييم
PE (TTM|NTM)
-6.40 | -4.08
أقل من متوسط القطاع (-1.49)
P/B Ratio1.57
EV/EBITDAN/A
Dividend YieldN/A
تاريخ السعر
الاتجاهات المالية
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1385 نظير)
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1385 نظير)| المقياس | السهم | وسيط القطاع |
|---|---|---|
| P/E | -6.4 | -1.5 |
| P/B | 1.6 | 1.6 |
| ROE % | -43.6 | -54.5 |
| Net Margin % | — | -41.5 |
| Rev Growth 5Y % | — | 1.9 |
| D/E | — | 0.3 |
السعر المستهدف للمحللين
6 محللين
Buy
الحالي
KWD 5.52
المستهدف
KWD 17.00
KWD 11.00
KWD 14.50
KWD 30.00
التوقعات
مكرر الربحية المستقبلي
-4.08
ربحية السهم المستقبلية
-KWD 1.35
الإيرادات المقدّرة
19.20 M
تقديرات الأرباح
| الفترة | تقدير ربحية السهم | تقدير الإيرادات | المحللون |
|---|---|---|---|
| FY2027 |
-KWD 1.35
-KWD 1.73 – -KWD 0.67
|
19.20 M | 6 |
| FY2026 |
-KWD 1.19
-KWD 1.37 – -KWD 0.99
|
0.0 | 6 |
| الفترة | تقدير ربحية السهم | تقدير الإيرادات | المحللون |
|---|---|---|---|
| 2026 Q2 |
-KWD 0.28
-KWD 0.32 – -KWD 0.25
|
0.0 | 5 |
| 2026 Q1 |
-KWD 0.25
-KWD 0.31 – -KWD 0.21
|
0.0 | 5 |
مفاجآت الأرباح
آخر 4 أرباع
| الربع | EPS المقدر | EPS الفعلي | المفاجأة |
|---|---|---|---|
| Q42025 | -KWD 0.31 | -KWD 0.18 | +42.3% |
| Q32025 | -KWD 0.39 | -KWD 0.38 | +2.2% |
| Q22025 | -KWD 0.40 | -KWD 0.40 | -0.5% |
| Q12025 | -KWD 0.59 | -KWD 0.42 | +28.2% |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -56.02 M |
| ROE | -43.61% | ROA | -39.86% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -45.49 M |
| ROIC | -35.52% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 24.00 |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | 219.56 M | Tangible Book Value | 220.96 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -6.40 | Forward P/E | -4.08 |
| P/B Ratio | 1.57 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | 18.69 | Fwd Earnings Yield | N/A |
| FCF Yield | -12.68% | ||
| Market Cap | 358.82 M | Enterprise Value | 131.26 M |
| Per Share | |||
| EPS (Diluted TTM) | -1.27 | Revenue / Share | N/A |
| FCF / Share | -0.70 | OCF / Share | -0.70 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 81.19% |
| SBC-Adj. FCF | -51.80 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | 0.0 | 316,952.0 | 2.08 M |
| Net Income | -56.02 M | -61.04 M | -53.47 M | -50.51 M | -33.54 M |
| EPS (Diluted) | -1.27 | -2.04 | -1.88 | -1.90 | -2.46 |
| Gross Profit | — | — | 0.0 | 158,830.0 | 926,888.0 |
| Operating Income | -59.38 M | -64.07 M | -58.41 M | -51.74 M | -33.89 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 42.05 M | 47.96 M | 41.62 M | 36.27 M | 26.54 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | 324,517.0 | 355,807.0 | — | — | — |
| Interest Expense | — | — | — | — | — |
| Income Tax | 0.0 | — | — | -307,485.0 | -307,485.0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 231.99 M | 52.71 M | 102.58 M | 122.37 M | 166.70 M |
| Total Liabilities | 13.50 M | 11.33 M | 12.01 M | 12.52 M | 10.72 M |
| Shareholders' Equity | 218.48 M | 41.39 M | 90.58 M | 109.85 M | 155.98 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 128.65 M | 36.14 M | 59.41 M | 72.64 M | 74.89 M |
| Current Assets | 176.25 M | 39.59 M | 89.08 M | 108.75 M | 152.33 M |
| Current Liabilities | 10.07 M | 7.50 M | 7.85 M | 8.05 M | 5.63 M |
{"event":"ticker_viewed","properties":{"ticker":"IMRX","listing_kind":"stock","pathname":"/stocks/imrx","exchange":"NASDAQ","country":"US"}}